Parkinson’s Disease Psychosis is Often Underdiagnosed and Undertreated: What Can You Do to Improve the Quality of Care for Your Patients?
Fernando L. Pagan, MD
Professor and Vice Chairman of Neurology
Director of Movement Disorders Program
Medical Director of Georgetown University Hospital
Parkinson Foundation Center of Excellence
Translational Neurotherapeutics Program
In this virtual program, we will explore the management of Parkinson’s disease psychosis (PDP)–a condition that affects a substantial percentage of patients with Parkinson’s disease, typically in the later stages. Through this interactive program, clinicians will recognize symptoms, features, and diagnostic best practices in PDP. In addition, participants will learn about the underlying pathophysiology of PDP and treatments targeting these underlying pathways pivotal to the progression of PDP. Through an improved understanding of PDP, clinicians will gain insights and tools to better manage patients with PDP. Through interactive case studies presented by expert faculty, learners will be able to better evaluate pharmacologic approaches to PDP management and the efficacy and safety of approved therapeutic options. In addition, engaging whiteboard animations presented throughout will reinforce concepts learned in didactic portion, ensuring that participants understand the pathophysiology and mechanisms involved in pharmacologic management of PDP.
This CME initiative is designed to meet the educational needs of US-based neurologists, psychiatrists, and other members of the multidisciplinary care team involved in the diagnosis and management of patients with PDP.
Upon the completion of this program, attendees should be able to:
- Facilitate a timely and accurate diagnosis of PDP
- Evaluate the evidence supporting different neurotransmitter-based theories of PDP pathophysiology that inform treatment targets and side effect profiles associated with currently available therapies
- Support coordinated patient-centered multidisciplinary team-based approaches for the long-term management of patients with PDP
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with PD.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Fernando Pagan, MD, reports that he has received consultation fees from Acorda, Adamas, Kyowa, Kirin, Neurocrine, Supernus, Teva, and has participated in speakers bureaus for Acadia, Acorda, Amneal, Kyowa Kirin, Neurocrine, Supernus, and Teva, owns stock in Keiferx LLC, and serves as co-founder and board member of Keiferx LLC.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
Mike Page, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Ashley Whitehurst, Program Manager for Med Learning Group, has nothing to disclose.
Natalie Smith, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this activity. To receive credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the activity.
- Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected].
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASE DATE: December 21, 2021
EXPIRATION DATE: December 21, 2022
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form other than personal use without the express written permission of Med Learning Group is prohibited.